Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 225-228

  Sinha, Binayak ^a   Gangopadhyay, Kalyan Kumar ^b   Ghosal, Samit ^c  

^a AMRI HOSPITALS   (India)

^b PEERLESS HOSPITAL   (India)

^c Nightingale Hospital   (India)

Author keywords

Degludec; Glargine; Hypoglycaemia; Insulin

Indexed keywords

ACARBOSE; ATORVASTATIN; CREATININE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN LISPRO; LINAGLIPTIN; LOSARTAN; METFORMIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CREATININE BLOOD LEVEL; DEHYDRATION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INDIA; INJECTION SITE BURNING; INJECTION SITE PAIN; INSULIN TREATMENT; KIDNEY TRANSPLANTATION; MALE; MICROALBUMINURIA; MIDDLE AGED; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; STUPOR; URINARY TRACT INFECTION;

EID: 84903269794     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S63878     Document Type: Article

References (19)

1. [No authors listed]. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249-1258.
2. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944-950.
3. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879-886.
4. Housel AK, Shaw RF, Waterbury NV. Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration. Diabetes Res Clin Pract. 2010;8(2):17-19.
5. Floch JL, Levy M, Mosnier-Pudar H, etal. Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care. 2009;32(1):32-37.
6. Mayfield J, White R. Insulin therapy for type 2 diabetes: rescue, augmentation and replacement of beta-cell function. Am Fam Physician. 2004;70(3):489-500.
7. Kurtzhals P, Heise T, Strauss HM, etal. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54 Suppl 1:S426.
8. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104-2114.
9. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864.
10. Keating GM. Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus. Drugs. 2013;73(6):575-593.
11. Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients of type 2 diabetes requiring high doses of basal insulin: meta-analysis of five randomized BEGIN® trials. Endocr Pract. 2013;20(4):285-290.
12. Heller S, Buse J, Fisher M, etal. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN® Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489-1497.
13. Mathieu C, Hollander P, Miranda-Palma B, etal. Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN®: Flex T1): a 26-week randomized treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154-1162.
14. Zinman B, Philis-Tsimikas A, Cariou B, etal. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN® Once Long). Diabetes Care. 2012;35(12):2464-2471.
15. Garber AJ, King AB, Del Prato S, etal. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN® Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-1507.
16. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan Asian, treat-to-target trial. J Diabetes Invest. 2013;4(6):605-612.
17. Meneghini L, Atkin SL, Gough SC, etal. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4): 858-864.
18. Gough S, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low volume insulin degludec 200 U/mL once-daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN® LOW VOLUME trial. Diabetes Care. 2013;36(9): 2536-2542.
19. Singh AK, Sinha B. Advances in basal insulin therapy: lessons from current evidence. J Indian Med Assoc. 2013;111(11):735-742.